Literature DB >> 32362270

COVID-19, Australia: Epidemiology Report 13 (Reporting week to 23:59 AEST 26 April 2020).

.   

Abstract

Confirmed cases in Australia notified up to 26 April 2020: notifications = 6,711; deaths = 77. The reduction in international travel and domestic movement, social distancing measures and public health action have likely slowed the spread of COVID-19 in Australia. Notifications in Australia remain predominantly among people with recent overseas travel, with some locally-acquired cases being detected. Most locally-acquired cases can be linked back to a confirmed case, with a small portion unable to be epidemiologically linked to another case. The ratio of overseas-acquired cases to locally-acquired cases varies by jurisdiction. The crude case fatality rate (CFR) in Australia remains low (1.1%) compared to the World Health Organization's globally-reported rate (6.9%) and to other comparable high-income countries such as the United States of America (5.1%) and the United Kingdom (13.7%). The lower CFR in Australia is likely reflective of high case ascertainment including detection of mild cases. High case ascertainment and prompt identification of contacts enables an effective public health response and a reduction of disease transmission. Internationally, cases continue to increase. The rates of increase have started to slow in several regions, although it is too soon to tell whether this trend will be sustained. Interpretation of international epidemiology should be conducted with caution as it differs from country to country depending not only on the disease dynamics, but also on differences in case detection, testing and implemented public health measures. © Commonwealth of Australia CC BY-NC-ND.

Entities:  

Keywords:  2019-nCoV; Australia; COVID-19; SARS-CoV-2; acute respiratory disease; coronavirus disease 2019; epidemiology; novel coronavirus

Mesh:

Year:  2020        PMID: 32362270     DOI: 10.33321/cdi.2020.44.35

Source DB:  PubMed          Journal:  Commun Dis Intell (2018)        ISSN: 2209-6051


  6 in total

1.  Adverse Events and Safety Profile of the COVID-19 Vaccines in Adolescents: Safety Monitoring for Adverse Events Using Real-World Data.

Authors:  Chae Won Lee; Soonok Sa; Myunghee Hong; Jihyun Kim; Sung Ryul Shim; Hyun Wook Han
Journal:  Vaccines (Basel)       Date:  2022-05-09

2.  Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.

Authors:  Timothy A West; Sameer Malik; Anastasios Nalpantidis; Tuan Tran; Christine Cannon; Deepak Bhonagiri; Kevin Chan; Elaine Cheong; Jenny Wan Sai Cheong; Winston Cheung; Faisal Choudhury; David Ernest; Claude S Farah; Shelanah Fernando; Rupa Kanapathipillai; Mark Kol; Brendan Murfin; Haider Naqvi; Asim Shah; Atul Wagh; Samar Ojaimi; Bradley Frankum; Sean Riminton; Karuna Keat
Journal:  Int J Rheum Dis       Date:  2020-08       Impact factor: 2.454

Review 3.  Newly Reported Studies on the Increase in Gastrointestinal Symptom Prevalence withCOVID-19 Infection: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Hakan Akin; Ramazan Kurt; Fatih Tufan; Ahmed Swi; Resat Ozaras; Veysel Tahan; Ghassan Hammoud
Journal:  Diseases       Date:  2020-11-10

4.  COVID-19 Testing in a Weekly Cohort Study of Gay and Bisexual Men: The Impact of Health-Seeking Behaviors and Social Connection.

Authors:  Mohamed A Hammoud; Nathanael Wells; Martin Holt; Benjamin Bavinton; Fengyi Jin; Lisa Maher; Steven Philpot; Bridget Haire; Louisa Degenhardt; Adam Bourne; Peter Saxton; Phillip Keen; Daniel Storer; Garrett Prestage
Journal:  AIDS Behav       Date:  2022-09-01

5.  Emerging viral mutants in Australia suggest RNA recombination event in the SARS-CoV-2 genome.

Authors:  Ting-Yu Yeh; Gregory P Contreras
Journal:  Med J Aust       Date:  2020-06-07       Impact factor: 12.776

6.  A multiple site community outbreak of COVID-19 in Sydney, Australia.

Authors:  Adam Capon; Dima Ousta; Mark Ferson; Andrew Ingleton; Vicky Sheppeard
Journal:  Aust N Z J Public Health       Date:  2021-02-22       Impact factor: 3.755

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.